Kirkland & Ellis advised investment firm Altaris, LLC on the pending acquisition of Minaris Regenerative Medicine from Resonac Corporation, a subsidiary of Resonac Holdings Corporation (TYO: 4004). Minaris is a cell therapy contract development and manufacturing organization that provides autologous and allogeneic manufacturing services for pharmaceutical and biotech customers globally. The transaction is expected to close in the first quarter of 2025 subject to customary closing conditions. Read the Altaris press release The Kirkland team was led by corporate partners David Feirstein and Michael Amalfe and associates Arjun Mocherla and Brandon Okun; technology & IP transactions partner Matt Darch; and tax partner Sara Zablotney.